Ruminations of a Taco-Obsessed Philly Native

Dr. Sameer Jejuirkar is based in Dallas, Texas and is a board-certified plastic surgeon and a member of the Dallas Plastic Surgery Institute. He focuses his craft on cosmetic surgery for the body, breast, eyes, face, and nose. Dr. Jejurikar has used his skills and training to help the less fortunate by participating in medical missions, including an annual trip with the organization Smile Bangladesh.

His education and training include being an undergraduate at the University of Michigan, attending University of Michigan Medical School and being part of the Alpha Omega Alpha Honor Society. His residency in plastic surgery took place at the University of Michigan Medical Center and his training in aesthetic surgery was at Manhattan Eye, Ear and Throat Hospital.

He has memberships and certifications from Alpha Omega Alpha Honor Society, American Society of Plastic surgeons, of which he is an active member. He is also an active member of the Dallas Society of Plastic Surgeons and American Society for Aesthetic Plastic Surgery and is a Diplomate for the American Board of Plastic Surgery and is a member of the American Medical Association.

He has had publications in the Aesthetic Surgery Journal, Annals of Plastic Surgery, Journal of Surgical Research and has written on Plastic & Reconstructive Surgery as well as Microsurgery. He is affiliated with three locations in Dallas, Texas, Dallas Day Surgery Center, Texas Health Presbyterian Hospital, and Texas Health Surgery Center Dallas.

According to prnewswire.com, he was ranked as one of the top physicians in the country and had been awarded the Compassionate Doctor Certificate. This is based upon feedback left by patients about their experiences with their physicians. Only the physicians with near perfect scores for bedside manner and overall scores are selected for this recognition and only 3% of the nation’s 870,000 active physicians were given this honor in 2012, which would be about 26,000 who were awarded.

Dr. Jejurikar also runs a blog on his website where he writes about a number topics ranging from basic skin care, liposuction, rhinoplasty, breast reconstruction, the use of lasers and fillers, as well as myths about breast implants.

 

One of the persistent problems that has plagued the use of chemotherapy throughout its existence has been the horrendous side effects associated with the use of this drug. Often times, patients are limited in the amount of chemotherapeutic agents they can be given at one time. This is simply due to the fact that the drug is so poisonous that it can actually directly lead to the patient’s death, by itself. This has severely limited the usefulness of chemotherapeutic regimens in some of the most difficult to treat cancer types.

 

Even so, the basic premise of chemotherapy is airtight. In theory, almost any tumor could be completely eliminated through the administration of chemotherapy. The only limiting factor is the amount of drug that a patient is able to tolerate. This has long vexed the medical establishment, leading to many efforts to increase the amount of chemotherapy that can be safely given to any patient group at a given time.

 

One of these efforts has led to the creation of so-called antibody drug conjugates. These targeted cancer therapies are able to use synthetic human antibodies as the means to directly deliver the chemotherapeutic agent, known as a cytotoxin, directly to the site of the tumor. They do this through the natural process that antibodies use to create molecular keys that directly fit only the specific tissue created by the tumor. In doing so, it is possible to use these natural defense mechanisms to bind cytotoxins directly to a delivery mechanism that only releases the poison upon direct contact with the malignant tissue.

 

Clay Siegall has been a leading figure in the development of this exciting new class of drugs. After founding his own company, Seattle Genetics, which is the sole pharmaceutical firm in the country dedicated solely to the creation of antibody drug conjugates, Dr. Siegall has made a name for himself as a leading innovator in the targeted cancer therapy space.

 

In 2011, Seattle Genetics was granted its first FDA approval for an antibody drug conjugate. This not only marks the company’s first FDA-approved drug but the first antibody drug conjugate ever approved for use in the wide market by that agency.